Talecris Underwrites Cost Of New Immune Deficiency E-Newsletter
Talecris is a manfacturer of liquid immune globulin intravenous therapy that is used to treat immune deficiency. Talecris provided a grant of an undisclosed amount to fund the newsletter.
Titled "Primary Immune Tribune", the newsletter will be delivered on a monthly basis. It will focus on resources, activities, and programs, and will help answer questions and provide quality educational information for patients and their families, the Immune Foundation said.
The first issue will be distributed in October.
"Talecris Biotherapeutics is extremely proud to be associated with such an important new informational tool," said Alberto Martinez, president and chief executive officer of Talecris. "As an industry leader with a long history of commitment to the primary immune deficiencies, Talecris recognizes the importance of collaborations, such as this one with IDF, that improve education and awareness to advance patient care. Talecris will remain a strong corporate citizen committed to these types of partnerships with the patient community."
To receive a free subscription of Primary Immune Tribune,send a request to enewsletter@primaryimmune.org.
Talecris: www.talecris.com
Copyright 2013 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
